A group of Fondazione IRCCS Estituto Neurologico Carlo Besta, Via Padova, Milan, Italy etc. believes that the low efficacy of antiviral drugs such as cytokine inhibitors is (1) probably due to delays in administration in which the virus causes an inflammatory response and is no longer the main protagonist, (2) the relatively low efficacy of cytokine inhibitors is explained because they only act on one or a few of the dozens of cytokines, and (3) other inflammatory mediators (reactive oxygen and nitrogen species) are not targeted.
When inflammatory mediators are over-generated, reactive species cause extensive cell and tissue damages. The only drug known to inhibit the over production of active species and cytokines is methylene blue, a low-cost dye with antiseptic properties that is effectively used in the treatment of malaria, urinary tract infections, septic shock, and methaemoglobinaemia. They suggest testing methylene blue to treat COVID-19 acute respiratory distress syndrome.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728423/